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Abstract
It has long been known that pregnancy and childbirth have a profound effect on the disease activity of
rheumatic diseases. For clinicians, the management of patients with RA wishing to become pregnant
involves the challenge of keeping disease activity under control and adequately adapting drug therapy
during pregnancy and post-partum. This article aims to summarize the current evidence on the evolution
of RA disease activity during and after pregnancy and the use of anti-rheumatic drugs around this period.
Of recent interest is the potential use of anti-TNF compounds in the preconception period and during
pregnancy. Accumulating experience with anti-TNF therapy in other immune-mediated inflammatory dis-
eases, such as Crohn’s disease, provides useful insights for the use of TNF blockade in pregnant women
with RA, or RA patients wishing to become pregnant.
Key words: Pregnancy, Rheumatoid arthritis, Disease activity, Pregnancy outcome, Drug treatment, Anti-TNF,
Review.
Introduction
The first observation that the symptoms of RA often ameli-
orate during pregnancy dates back to the landmark pub-
lication of Hench in 1938 [1] and has been confirmed
many times since then. The mechanisms responsible for
decreased disease activity during pregnancy and
post-partum flare of RA, however, have remained elusive,
although the potential role of a number of immunological
and hormonal factors has been described. In AS, disease
activity does not seem to be influenced by pregnancy,
whereas in SLE an increased risk of disease flares
has been described both during pregnancy and the
post-partum period, especially in patients with active
disease at conception.
For rheumatologists, the management of RA patients
wishing to become pregnant involves adaptation of the
therapeutic regimen, thereby balancing the need to with-
draw teratogenic drugs, such as MTX and LEF, while
keeping disease activity under control. In the rheumato-
logical setting, little data are available on the use of
anti-TNF therapy in the preconception period or during
pregnancy in RA women.
This article reviews the effect of pregnancy on disease
activity in RA, discusses the effects of disease activity on
pregnancy outcome and gives an overview of drug use
before and during pregnancy and lactation. In particular,
literature data on the use of anti-TNF therapy during preg-
nancy in immune-mediated diseases are summarized in
order to provide guidance on whether anti-TNF therapy is
safe and useful to treat pregnant RA patients or RA pa-
tients wishing to become pregnant.
Effect of pregnancy on disease activity
Since the publication by Hench [1], several studies have
confirmed the spontaneous improvement of RA during
pregnancy and an increased risk of flare after delivery
[27] (Table 1). Hench [1] reported improvement in 33 of
34 pregnancies recalled by 20 patients, while Oka
observed symptomatic improvement, mostly starting in
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Johanna M.W. Hazes et al.the first trimester, in 77% of patients, and post-partum
flare within 4 months after delivery in 81% [4]. In a study
by Ostensen et al. [7], pregnancy-associated remission of
RA was reported in 75% of patients, with post-partum
exacerbation in 62%. Klipple and Cecere [5] reported
 70% of patients improving during pregnancy, with
>90% of them experiencing a disease relapse in the
first year post-partum. A study of 57 pregnancies in
41 women by Nelson et al. [6] found remission in
22 (39%) and improvement of the disease in 12 (21%)
pregnancies.
These high remission or improvement rates need to be
interpreted with caution, as the data mostly come from
small retrospective analyses that use various definitions
of disease activity and clinical amelioration, often rely on
patients’ recall of symptoms, and sometimes fail to use
validated clinical measurements of disease activity.
Pregnancy itself has been shown to influence the meas-
urement of disease activity [8, 9]. In a comparison of dif-
ferent disease activity scoring tools in pregnant women
with RA vs healthy controls, 28-joint DAS (DAS-28)-CRP
without assessment of global health was the preferred
tool for measuring RA disease activity in pregnant
patients [8, 9].
In the UK, a nationwide prospective study of 140 preg-
nant women with RA, recruited during pregnancy and fol-
lowed until 6 months post-partum, reported improvement
in joint swelling and pain in about two-thirds of patients,
although the extent of improvement was limited, with only
16% of women reaching remission during pregnancy [10].
More recent prospective studies using validated clinical
tools to measure RA disease activity confirmed the
improvement of RA during pregnancy and increased risk
of flares post-partum, but the extent of improvement was
smaller than in earlier studies. Ostensen et al. [11] re-
ported a decrease in disease activity during pregnancy,
measured with several validated clinical tools [swollen
joint count, RA disease activity index (RADAI) score and
HAQ] in a small group of 10 RA patients. The Dutch
Pregnancy-induced Amelioration of Rheumatoid Arthritis
(PARA) study [12] prospectively evaluated disease activity
using DAS-28-CRP-3 in RA patients fulfilling the ACR
criteria for RA and recruited between 2002 and 2006.
Mean disease activity scores significantly decreased
during pregnancy and increased post-partum. Overall,
39% of patients improved during pregnancy, mirrored
by flares observed in 38% of patients from 12 to 26
weeks post-partum. The highest impact on disease activ-
ity was observed in patients with moderate or high
disease activity in the first trimester. Improvement of RA
was observed despite the concomitant reduction of drug
therapy: MTX, LEF and biologicals were not used at all
during pregnancy in this study.
Apart from the use of more objective disease activity
measurements and elimination of recall bias, the fact
that treatment options for RA have substantially improved
over the past decade offers an additional explanation why
recent prospective studies yield lower improvement rates
than older retrospective studies. Better disease control
before conception obviously leaves less room for
pregnancy-associated amelioration.
Pregnancy not only mitigates disease activity in RA pa-
tients, but also decreases the risk for RA onset [1315].
According to Lansink et al. [13], this protective effect lasts
until the first 3 months post-partum, whereas other
studies observed a higher risk to develop RA in the first
6 months [4] or the first year post-partum [14]. A
Norwegian registry study found a peak RA incidence in
the first 2 years after delivery [16]. Women who have
ever been pregnant have an almost 2-fold lower risk of
getting RA [14, 1719], and a better outcome if they do
get RA [20]. Additionally, multiple pregnancies may have
a slightly beneficial effect on the long-term disease
outcome of RA, with slightly fewer erosions and better
functional level [21].
Except for a slight decrease in fecundity [6] and a
modest risk of prematurity and low birthweight in patients
with highly active disease, the course and outcome
of pregnancy in RA patients are generally favourable
[22, 23]. In the Dutch PARA study, lower birthweight of
babies born to RA patients was independently associated
with active disease in the third trimester of pregnancy, and
indirectly with prednisone use, which was associated with
shorter gestational age [22].
Potential mechanisms mediating the
effect of pregnancy on disease activity
Despite intensive research, the main factors responsible
for the favourable influence of pregnancy on RA remain
largely unknown. Decreased RA disease activity during
pregnancy may well be the net result of complex
pregnancy-related hormonal and immunological alter-
ations (reviewed in [23]). Clinical improvement of RA is
not reflected by parallel changes in anti-CCP or RF
levels, although patients negative for anti-CCP and RF
were more likely to improve during pregnancy [24].
A number of hormonal and immunological factors
that undergo extensive changes during pregnancy have
been investigated with respect to their contribution
to the pregnancy-associated RA amelioration. So far,
serum levels of cortisol, sex hormones and alpha-2
pregnancy-associated globulin (PAG) have been studied,
but did not provide a satisfactory explanation for the im-
provement of RA during pregnancy and its relapse after
delivery.
Although the discovery of CSs as therapy for RA by
Hench [1] was linked to his initial observation of clinical
improvement in pregnant RA patients, increased serum
cortisol levels during pregnancy cannot account for the
pregnancy-associated decrease in disease activity [25].
The concurrence of rises in alpha-2 PAG and amelioration
of disease symptoms during pregnancy was not consist-
ent across different studies [2628] and the value of PAG
as a parameter of disease activity in RA is limited [29]. The
higher prevalence of rheumatic and autoimmune diseases
in women [30] prompted investigation into the role of sex
www.rheumatology.oxfordjournals.org 1957
RA and pregnancyhormone levels in pregnancy-associated remission.
Increases in oestrogen and progesterone levels may
play an indirect role by their effect on the immune re-
sponse [14, 17, 3033]. The combined effect of increased
levels of cortisol, oestrogen and vitamin D has been impli-
cated in lowering the pro-inflammatory cytokines, IL-12
and TNF-a, during pregnancy [34].
Disease flares post-partum have been linked to a rise in
prolactin levels in breastfeeding mothers, as increased RA
disease activity at 6 months post-partum was observed in
first-time breastfeeding mothers [35]. Prolactin has been
described as an immunomodulatory molecule with certain
inflammatory effects and a potential role in autoimmunity
[36, 37], but whether breastfeeding influences the risk of
developing RA remains controversial, since other studies
observed a protective effect of breastfeeding on future RA
risk [38, 39].
Increased galactosylation of serum IgG correlated with
disease remission in a small study with 23 pregnant RA
patients [40]. These findings were later confirmed in a
larger cohort study [41]. In view of the important function
of oligosaccharide modifications of immunoglobulins [42],
IgG galactosylation is thought to diminish the antigenicity
and pro-inflammatory properties of Ig autoantibodies such
as RF. Arguments for this hypothesis are mainly derived
from animal models where arthritis could only be induced
by infusion of agalactosyl IgG and not by galactosylated
IgG [43, 44]. Whether changes in IgG galactosylation
are a mere epiphenomenon or a causative factor in
pregnancy-related reduction in disease activity remains
a matter of debate [42].
Pregnancy is a situation of induced immunological tol-
erance in the mother against the semi-allogeneic fetus.
Immunological changes in pregnancy necessary for this
so-called feto-maternal tolerance are summarized in
Fig. 1 and include thymic involution [45], decreased NK-
cell function [46], and a decrease in Th1 immune response
shifting towards a more Th2-dominated immune response
pattern [17, 31, 47], whereas T- and B-cell numbers, anti-
body production and response to vaccines do not change
during pregnancy.
Although from the second trimester of pregnancy on,
shed trophoblast cells bring fetal antigens into contact
with the maternal immune system, pregnancy is not a
state of general immunosuppression, as the main mech-
anisms inducing tolerance towards the fetus are only
active at the feto-maternal interface. Syncytiotrophoblast
cells express the complement inhibitors, decay-
accelerating factor (DAF), membrane cofactor protein
(MCP) and cluster of differentiation 59 (CD59), thereby
protecting fetal cells from complement-mediated lysis
[48]. T-cell activation at the feto-maternal interface is in-
hibited by the local expression of indoleamine-2,3-
dioxygenase (IDO). IDO degrades the amino acid trypto-
phan, which in T cells is an essential amino acid required
for T-cell activation, thereby inducing a strictly local,
FIG.1Mechanisms of feto-maternal tolerance. Pregnancy is a situation of induced immunological tolerance in the
mother against the semi-allogeneic fetus. The immunological mechanisms responsible for this state of tolerance consist
of local components, triggered by trophoblast-induced changes in uterine cytokine profile, decreased T- and NK-cell
function and complement activation. In addition, systemic changes in immune function during pregnancy include
progesterone-induced thymus involution, decreased NK-cell activity and a shift towards a more Th2-dominated
immune-response pattern. KIR: killer cell immunoglobulin-like receptor; uNK: uterine natural killer cell.
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Johanna M.W. Hazes et al.reversible T-cell anergy [49]. Trophoblast cells have a spe-
cial HLA expression pattern. They do not express HLA-A,
HLA-B or Class II molecules, but instead express only
HLA-C molecules in addition to the non-classical HLA-E
and HLA-G molecules, all of which interact with inhibitory
receptors on NK cells. The most specific embryonic
signal, human chorionic gonadotrophin (hCG), plays an
active role in implantation of the embryo, placental angio-
genesis and tolerance of the fetal allograft through stimu-
lation of endometrial leukaemia inhibitory factor (LIF) and
VEGF, as well as inhibition of endometrial IL-6, respect-
ively [50]. Finally, Tregs have been shown to accumulate
at the feto-maternal interface [31], in response to fetal
hCG secretion [51]. Tregs at the feto-maternal interface
protect the fetus by inhibiting activation of effector T
cells by expressing the inhibitory cytokines IL-10 and
TGF-b, by lysing effector T cells or by inhibiting the mat-
uration and function of dendritic cells [17]. Treg dysfunc-
tion or deficiency has also been implicated in the
pathogenesis of RA. The number of Tregs in pregnant
women with RA was found to correlate inversely with RA
disease activity in the third trimester of pregnancy and
post-partum [17]. The immunological effects of exposure
to fetal antigens during pregnancy may contribute to both
reducing RA risk as well as mitigation of disease activity
during pregnancy, as several studies have shown these
effects to be correlated with the degree of materno-fetal
HLA class II disparity [39, 52, 53].
Drug treatment of RA during
preconception, pregnancy and lactation
Counselling RA patients wishing to become pregnant and
treating RA during pregnancy and post-partum can be
quite a challenge to the clinician, since several RA
medications are contraindicated during pregnancy and
lactation, leaving only a limited number of therapeutic op-
tions. Ethical constraints prevent the evaluation of the
safety of drugs for use in pregnancy during pre-marketing
clinical trials, and post-marketing assessment of terato-
genicity poses a number of methodological difficulties
[54, 55]. Therefore, drug safety information for use in preg-
nant patients heavily relies on safety classification sys-
tems such as the Food and Drug Administration (FDA)
categories for drug use in pregnancy (Table 2). This
latter classification system places a lot of potentially
harmless drugs in Category C due to a lack of sufficient
data from controlled studies in humans.
Additional drug safety data often come from voluntary
reports of adverse events during post-marketing surveil-
lance or from uncontrolled observational studies or clinical
experience. These data are obviously poor sources for
evidence-based clinical decision making, since they are
mostly retrospective, are subject to recall and publication
bias, do not include accurate exposure data, are limited
with respect to follow-up of patients or do not include a
comparator population. So the clinical management of
pregnant RA patients suffers from the wide gap between
formal safety data and the need to make therapeutic
decisions for adequate disease control in daily clinical
practice [54, 56].
Since RA disease activity is likely to improve during
pregnancy in a majority of patients, with a subset of pa-
tients even achieving remission, the most critical period is
the preconception period in the case of planned preg-
nancy. In this period, conventional DMARDs with terato-
genic properties must be stopped, while low disease
activity needs to be preserved. Table 3 gives an overview
of the FDA categories of drugs commonly used in RA
treatment and summarizes the current recommendations
TABLE 2 US Food and Drug Administration categories for drug safety during pregnancy [56]
FDA category Description
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus during the first
trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and
well-controlled studies in pregnant women.
Or
Animal reproduction studies have shown an adverse effect, but adequate and well-controlled stu-
dies in pregnant women have failed to demonstrate a risk to the fetus during the first trimester of
pregnancy (and there is no evidence of a risk in later trimesters).
C Animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and
well-controlled studies in humans, and the benefits from the use of the drug in pregnant women
may be acceptable despite its potential risks.
Or
There are no animal reproduction studies and no adequate and well-controlled studies in humans.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or
marketing experience or studies in humans, but the potential benefits from the use of the drug in
pregnant women may be acceptable despite its potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities or there is positive evidence of
fetal risk based on adverse reaction reports from investigational or marketing experience, or both,
and the risk of the use of the drug in a pregnant woman clearly outweighs any possible benefit.
www.rheumatology.oxfordjournals.org 1959
RA and pregnancyfor their use in pregnant patients or patients wishing to
become pregnant.
NSAIDs
NSAIDs generally fall into FDA Category B and most of
them can be used safely in the first part of pregnancy,
although increased risk [odds ratio (OR)=1.8, 95% CI
1.0, 3.2] of first trimester miscarriage under NSAID treat-
ment has been reported [57]. The risk associated with
NSAID use increases with pregnancy duration, since
NSAIDs used late in pregnancy can cause premature
closure of the ductus arteriosus and increase the risk of
neonatal bleeding [58]. Moreover, NSAID use in preg-
nancy has been associated with reversible impairment of
fetal renal function and the development of oligohydram-
nios, in which case immediate discontinuation of NSAID
administration is required [58]. Most NSAIDs therefore
receive an FDA Category C labelling beyond 30 weeks
of gestation.
Data on the use of selective cyclo-oxygenase-2 (COX-2)
inhibitors during pregnancy are scarce, hence these drugs
are not recommended for treating RA inflammatory symp-
toms during pregnancy [58, 59]. Moreover, the use of
COX-2 inhibitors for prevention of premature labour in
at-risk pregnancies was associated with a reversible
negative effect on fetal renal function and an increased
incidence of delivery before 37 weeks of gestation [60].
Most NSAIDs are considered safe during lactation,
although they are excreted in milk in low quantities.
Aspirin should not be used in doses exceeding
100mg/day. Feeding immediately before administration
of the drug can help to limit drug exposure in infants
[59, 61, 62].
CSs
CSs at doses up to 15mg/day (prednisolone equivalent)
are believed to be safe throughout pregnancy [58]. Higher
doses increase the risk of infection and premature delivery
[59]. Systemic treatment with CSs during the first trimester
of pregnancy is believed to slightly augment the risk of
oral clefts, from 1 per 1000 live births to 1.33.3 per
1000 live births [63]. In the PARA study, the use of CSs
during pregnancy in RA patients was associated with
lower gestational age at delivery and increased incidence
of premature delivery, even at doses <7.5mg/day.
Women taking prednisone delivered on average 1 week
earlier [22].
Pregnant women are preferably treated with prednisone
or prednisolone, as these CSs are largely converted to
inactive metabolites by placental 11b-hydroxy steroid de-
hydrogenase, the mechanism in place to protect the fetus
from raised levels of maternal cortisol during pregnancy.
When the fetus is the target of corticoid therapy, dexa-
methasone or betamethasone are the compounds of
TABLE 3 Anti-rheumatic drugs and risk during pregnancy
Drug class FDA category Clinical recommendations
Symptom-modifying drugs
NSAIDs B First part of pregnancy
C After 30 weeks of gestation. Increased risk of premature closure of the ductus
arteriosus
CSs C Use during the first trimester is associated with increased risk of oral cleft in the
newborn
Increased risk of adrenal insufficiency
DMARDs
SSZ B No increased risk of congenital malformations
Combine with folate supplements
AZA D Can be continued to maintain remission during pregnancy
MTX X Contraindicated in pregnancy
Discontinue 36 months before conception
LEF X Contraindicated in pregnancy
Discontinue 2 years before pregnancy or use cholestyramine washout
procedure until plasma levels are <0.02mg/ml on two measurements spaced
at least 2 weeks apart
Anti-malarials C HCQ is compatible with pregnancy
Risk for retinal toxicity and ototoxicity higher for chloroquine than for HCQ
Biologicals
Anti-TNF B Anti-TNF antibodies are not transferred to the embryo/fetus in first trimester
of pregnancy
Abatacept C No human pregnancy data available
Discontinue 10 weeks before planned pregnancy
Rituximab C Reversible B-cell depletion or lymphopenia in the neonate
Long half-life. Discontinue 1 year before planned pregnancy
Tocilizumab C No human pregnancy data available.
Discontinue 10 weeks before planned pregnancy
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[64, 65].
Corticotherapy is also considered safe during lactation
[62]. Prednisolone is secreted in milk at doses estimated
at <0.1% of the maternal dose, which is thought to cor-
respond to <10% of the infants endogenous cortisol
level [66].
MTX
MTX is a known teratogen and as such is contraindicated
during pregnancy (FDA Category X; Table 2). MTX causes
embryotoxicity and teratogenicity in mice, rats and rab-
bits. In humans, the aminopterin syndrome, consisting of
growth deficiency and major CNS, bone and cardiac
abnormalities, has been described in children born after
exposure to MTX in the first trimester of pregnancy [67].
In view of the long tissue retention time of the active
metabolites of MTX, its administration must be stopped
36 months before conception [68]. MTX is a folic acid
antagonist. Therefore, folic acid supplementation after
MTX discontinuation is very important. Past exposure to
MTX has no negative effects on pregnancy outcomes [69].
A recent systematic review found that the risk of minor
birth defects after conception while using low-dose MTX
(515mg/week) is  5%, with no indication of the serious
aminopterin syndrome, and questions whether elective
abortion is required for pregnancies conceived during
low-dose MTX therapy [68]. MTX is excreted into breast
milk in low concentrations [66], but can accumulate in the
infant’s tissues, and is therefore contraindicated during
lactation.
LEF
LEF blocks de novo pyrimidine synthesis by inhibiting
dihydroorotate-dehydrogenase, and additionally inhibits
protein tyrosine kinase activity. Animal reproduction stu-
dies indicate that LEF is both embryotoxic and teratogen-
ic, mainly leading to craniofacial, skeletal and
cardiovascular malformations [70], which caused the
FDA to classify this drug in pregnancy Category X. Due
to the long half-life of its metabolites, LEF should be dis-
continued for 2 years before pregnancy. Alternatively, a
washout procedure with cholestyramine should be used
until plasma levels are <0.02mg/ml on two separate
measurements at least 2 weeks apart [71].
A recent prospective study compared pregnancy out-
comes in 64 RA patients exposed to LEF during preg-
nancy (61 of which underwent a cholestyramine washout
procedure), 108 RA patients not exposed to LEF and 78
healthy controls. In this study, the overall rate of major
structural defects between the studied groups was not
significantly different, nor did prenatal LEF exposure give
rise to a specific pattern of major or minor anomalies [72].
LEF is secreted into breast milk and therefore continues to
be contraindicated during breastfeeding [59, 73].
SSZ
It is generally regarded as safe to keep using SSZ during
pregnancy (FDA Category B drug), despite some reports
noting a higher incidence of neural tube defects, oral
clefts and cardiovascular defects. The outcome of preg-
nancies exposed to SSZ has mainly been studied in
women with IBD. A number of studies have concluded
that SSZ use during pregnancy does not give rise to
increased rates of birth defects in women with IBD when
compared with untreated IBD patients or the general
population [74, 75]. In a recent meta-analysis treatment
of IBD patients with 5-ASA, these drugs did not signifi-
cantly increase the risk of congenital abnormalities
(OR=1.16, 95% CI 0.76, 1.77, P=0.57), stillbirth
(OR=2.38, 95% CI 0.65, 8.72, P=0.32), spontaneous
abortion (OR=1.14, 95% CI 0.65, 2.01, P=0.74), preterm
delivery (OR=1.35, 95% CI 0.85, 2.13, P=0.26) or low
birthweight (OR=0.93, 95% CI 0.46, 1.85, P=0.96) [76].
SSZ therapy should be accompanied by extra folate
supplementation, as this medication halts folate synthesis
by inhibiting dihydrofolate reductase. Folic acid supple-
mentation was shown to decrease the augmented risk
of oral clefts and cardiovascular anomalies associated
with folate antagonist treatment during pregnancy [77].
The SSZ metabolite sulphapyridine is secreted into
breast milk. SSZ is generally considered safe during lac-
tation, although a case of bloody diarrhoea in an infant has
been reported [62, 78].
Anti-malarial agents
Use of HCQ during pregnancy at the low doses used for
malaria prophylaxis does not increase the risk of congeni-
tal abnormalities or pregnancy loss [79]. When used as a
DMARD at much higher doses, the continuation of this
drug during pregnancy has long been controversial and
the FDA classifies HCQ in Category C. This controversy
was mainly due to reports on retinal toxicity and ototox-
icity observed after treatment with chloroquine [80].
HCQ use during pregnancy has been reported in more
than 250 pregnancies in SLE patients, with no indications
for increased congenital malformations or hearing or
vision impairment. A more limited number of children
exposed to HCQ have been assessed for retinal toxicity
or cardiac conductivity disturbances, again with no indi-
cations of adverse effects of the drug. HCQ is secreted
into milk at low concentrations, but in view of the trans-
placental crossing of the drug and the relatively long
tissue half-life, it is not deemed necessary to advise
against lactation of children exposed to the drug during
pregnancy [80].
AZA
AZA and 6-mercaptopurine (6-MP) are designated as FDA
Category D drugs (Table 2), indicating that increased risk
for the fetus exists, but the risk must be weighed against
the possible benefits of the drug. Although AZA is terato-
genic in animals, inducing skeletal and visceral malforma-
tions in rabbits and mice at doses equivalent to the human
dose, multiple case series and cohort studies in human
pregnancy, mostly in transplant recipients and IBD
patients, have not revealed increased incidence of
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tions [74, 8185].
A recent cohort study in Denmark, including birth out-
comes of 76 exposed pregnancies, showed an increased
risk of preterm delivery and low birthweight in women
exposed to AZA or 6-MP during pregnancy, but no signifi-
cant increase in congenital malformations. However, the
data suggest that adverse birth outcomes are caused by
the underlying disease rather than by use of AZA or
MP [86].
Thiopurines undergo a complex metabolization pro-
cess and the placenta forms a partial barrier to their
metabolites. Indeed, the active metabolites 6-thioguanine
nucleotides (6-TGN) are detectable in fetal red blood cells,
whereas 6-methylmercaptopurine (6-MMP) is not [87].
Dosing 6-TGN at least once during pregnancy is recom-
mended to avoid excessively high levels, which may
cause myelosuppresson in mother and child [86].
Traditionally, breastfeeding is believed to be contraindi-
cated under thiopurine treatment, but several recent stu-
dies have shown that 6-MP levels in breast milk are low,
and conclude that breastfeeding during treatment with
AZA seems safe [8789].
Anti-TNF therapies
The currently available TNF inhibitors (etanercept, inflixi-
mab, adalimumab, golimumab and certolizumab) are all
classified as FDA Category B drugs, indicating that no
teratogenic effects of these drugs were observed in
animal reproduction studies, but adequate and controlled
human safety data are still lacking.
TNF-a is a pleiotropic cytokine that, in addition to being
a pivotal cytokine in the pathogenesis of immune-
mediated inflammatory disorders, plays a role in various
host defence mechanisms and in regulating and maintain-
ing pregnancy. TNF-a and its receptors are expressed in
the uterus, placenta and embryo, but surprisingly, pup
morphology, litter size and growth of TNF-a knockout
mice were not significantly different from wild-type con-
trols [90]. When exposed to the teratogen CYC, however,
fetuses from TNF-a knockout mice showed significantly
higher proportions of malformations, indicating that
TNF-a plays a role in protecting the fetus against terato-
genic stress [91]. Administration of the TNF inhibitors
during pregnancy and lactation did not influence the
number or function of immune-competent cells in mice
[92] or macaques [93], although another study reported
growth retardation as well as atrophy of the thymus,
spleen and lymph nodes in pups born to mice treated
with anti-TNF antibodies [94].
Despite the roles of TNF in establishing and maintaining
pregnancy and protecting the fetus, IgG anti-TNF antibo-
dies can probably be safely administered during the first
part of pregnancy, since IgG antibodies do not cross the
placental barrier in the first trimester. Indeed, transplacen-
tal transport of IgG only starts after the first trimester and
mainly increases during the third trimester of pregnancy
[95]. IgG levels in the maternal circulation decrease during
pregnancy, concomitant with a rise of IgG from maternal
origin in the fetal circulation starting from Week 13 on-
wards. At term, IgG levels in the fetus exceed the levels
in the maternal circulation, which is indicative of an active
transport mechanism (Fig. 2) [96]. Transplacental trans-
port was shown to be most efficient for the IgG1 and
least efficient for the IgG2 subclass [96]. IgG is trans-
ported over the placenta via pH-dependent receptor-
mediated transcytosis, in which maternal IgG binds to
the so-called neonatal immunoglobulin constant fragment
(Fc fragment) receptor expressed on the syncytiotropho-
blast membrane, followed by transcytosis and release of
bound IgG in the fetal circulation (Fig. 3) [9799].
Certolizumab is a PEGylated Fab0 fragment of an
anti-TNF mAb without Fc fragment. Certolizumab would
therefore be expected not to be transferred across the
placental barrier according to the mechanism described
above. Indeed, animal studies report much lower placen-
tal transfer of PEGylated Fab0 antibodies; data in humans
are not yet available, but a case of certolizumab adminis-
tration as rescue therapy in the third pregnancy trimester
of an IBD patient had a favourable outcome [100].
A review of more than 120000 adverse events recorded
in the FDA drug surveillance database revealed 61 con-
genital anomalies in 41 children born to women treated
with etanercept or infliximab during pregnancy. These
anomalies could be classified into 34 different types, 19
of which were associated with the so-called VACTERL
syndrome [101]. VACTERL is an acronym for congenital
syndromes characterized by the following birth defects:
vertebral, anal atresia, cardiac abnormalities, tracheoeso-
phageal fistula, oesophageal atresia, renal abnormalities
and limb abnormalities. This study was criticized for the
inherent selection bias in the reporting of anomalies, the
lack of sensitivity analysis taking into account co-existing
FIG.2Evolution of maternal and serum IgG levels during
pregnancy [94, 95]. IgG levels of maternal origin in the
fetal circulation increase over the course of pregnancy.
At the end of gestation, fetal IgG levels exceed those in
the maternal circulation, which indicates that the
placenta develops an active transport mechanism for IgG
molecules. Adapted from Malek A, Sager R, Kuhn P,
Nicolaides KH, Schneider H. Evolution of maternofetal
transport of immunoglobulins during human pregnancy.
Am J Reprod Immunol 1996;36:24855, with permission
from John Wiley & Sons Ltd.
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ported were among the most common in the population
and the fact that none of the reported cases showed three
anomalies, necessary for formal VACTERL diagnosis.
These criticisms cast doubts on the validity of the as-
sumption that TNF inhibitors cause congenital defects of
the VACTERL type [102, 103].
Apart from the VACTERL controversy, accumulating
data on anti-TNF treatment in RA during pregnancy has
not yielded any indications of teratogenicity or adverse
outcomes [104111]. Although the indications that
anti-TNF therapy is not teratogenic are growing as the
number of pregnancies exposed to anti-TNF during pre-
conception and early pregnancy increases, experience
with anti-TNF therapy in pregnant arthritis patients is still
quite limited [58, 112].
Probably rheumatologists can learn from the more
extensive experience with anti-TNF treatment during
pregnancy that exists already for IBD. In the latter disease
context, the need for effective treatment during pregnancy
is higher than in RA, because IBD disease activity is less
suppressed by pregnancy [113, 114]. Additionally, the
abdominal location of the disease raises the stakes of
maintaining disease remission during pregnancy in IBD,
as IBD disease flares during pregnancy carry a high risk
of adverse birth outcomes, including prematurity, low
birthweight and congenital abnormalities [115]. These
considerations have prompted gastroenterologists to
build more extensive experience with anti-TNF treatment
during pregnancy. A number of studies report intentional
use of anti-TNF treatment during pregnancy [108, 116,
117], and the 2010 European Crohn’s and Colitis
Organisation (ECCO) guidelines state that ‘medical treat-
ment for Crohn’s disease (except methotrexate) should
generally continue during pregnancy, because the bene-
fits outweigh the risk of medication’ [118].
Although experience is still limited, the fact that
anti-TNF antibodies do not cross the placenta in the first
trimester of pregnancy together with the overall unremark-
able outcome of pregnancies in women treated with TNF
inhibitors lead us to the opinion that TNF blockers can be
useful in RA patients to keep disease activity under con-
trol in the preconception period after withdrawal of terato-
genic DMARDs and in the first trimester of pregnancy.
Abatacept
Abatacept is a cytotoxic T-lymphocyte antigen 4 (CTLA4)
human immunoglobulin fusion protein that selectively
blocks T-cell co-stimulation through the CD80/CD86
pathway. Abatacept crosses the placenta, but animal stu-
dies with abatacept have revealed no congenital abnorm-
alities. Human pregnancy data are still lacking. Hence
this drug received an FDA Category C classification and
it is advised to discontinue therapy for 10 weeks before
conception [58]. Since no data are available currently on
the secretion of abatacept into milk, breastfeeding is
contraindicated during abatacept treatment [119].
Rituximab
Animal reproduction studies did not observe fetotoxicity
caused by the anti-CD20 mAb rituximab, which depletes
B cells. Scant data are available on the outcome of human
pregnancies exposed to rituximab. Consequently the FDA
classifies this drug in Category C.
The eight case reports of rituximab treatment during
pregnancy have reported reversible B-cell depletion and
lymphopenia in the neonate, but no congenital malforma-
tions. Due to its long-lasting effects, it is recommended
that rituximab treatment be stopped 1 year before con-
ception [79]. Currently data on secretion of rituximab in
breast milk are still lacking, hence the safety of this
biological during lactation cannot be guaranteed [119].
FIG.3Active transplacental transport mechanism for IgG. Fc receptors on syncytiotrophoblast cells at the feto-maternal
interface bind IgG from the maternal circulation in a pH-dependent way, transport it over the syncytiotrophoblast
cells via transcytosis, and release the bound IgG in the fetal circulation.
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Preclinical studies have not observed adverse effects of
tocilizumab on fertility or fetal development. In cynomol-
gus monkeys, small increases in abortion rates and fetal
mortality rates were observed, but these effects only
occurred at tocilizumab doses >100-fold the dose used
in humans. No pregnancies under tocilizumab therapy
have been reported up to now [117]. Currently it is advised
to discontinue tocilizumab therapy 3 months before
planned pregnancy [58]. Data on excretion of tocilizumab
in breast milk are not available at present [120].
Summary
Approximately two-thirds of RA patients experience a de-
crease in disease activity during pregnancy. Hormonal
and immunological changes associated with pregnancy
have been implicated to explain this effect, but its mech-
anisms remain largely elusive.
Treatment options for RA before conception and during
pregnancy are limited because of the teratogenicity of
DMARDs such as MTX and LEF. HCQ, SSZ and AZA
are compatible with pregnancy, as are CSs in doses up
to 15mg/day (prednisolone equivalent) and NSAIDs in the
first half of the pregnancy.
Current experience from IBD suggests that anti-TNF
therapy is a safe and useful option to bridge the period
between discontinuation of teratogenic DMARDs and
conception, or during the first trimester of pregnancy for
RA patients with aggressive disease. Clinical experience
with the newer biologicals in pregnancy is scarce to
non-existent, so it is safest to stop these drugs before
conception.
Rheumatology key messages
. RA disease activity, measured by validated instru-
ments, decreases during pregnancy in approxi-
mately two-thirds of patients.
. Anti-TNF is acceptable to control RA disease activ-
ity in the period directly preceding conception.
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Vasculitis of the temporal artery in a young woman
A 35-year-old Caucasian woman was referred for investi-
gation of a 14-month history of a solitary, painless, itchy
nodule in the left temporal region. It was hard and pulsatile
on palpation, with no overlying skin changes (Fig. 1A).
Her medical history and laboratory examinations were
negative. Ultrasonography demonstrated wall thickening
of a branch of the superficial temporal artery (TA)
with hypoechoic halo (Fig. 1B) and normal colour
Doppler pattern (Fig. 1C). On MRI Fast SpinEcho
T2-weighted fat-suppressed coronal sequences, hyperin-
tense tissue was seen around the vessel (Fig. 1D). The
differential diagnosis included juvenile temporal arteritis,
Kimura’s disease and angiolymphoid hyperplasia [1].
Histopathological examination (Fig. 1E) revealed perivas-
cular lymphocyte infiltration with lymphoid follicles and
vasa vasorum proliferation (arrows). This pattern, in asso-
ciation with the normal appearance of the TA and
only minimal reactive intimal hyperplasia of endothelial
cells, suggested Kimura’s disease. An asymmetric
US halo sign around the TA has been shown in both
angiolymphoid hyperplasia and juvenile temporal arteritis,
while its MRI appearance has not been described yet in
these conditions. In our patient, US and MRI features were
similar to those described in elderly type giant cell arteritis.
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FIG.1Clinical, ultrasonographic, MRI and histological
appearance of Kimura’s disease. (A) Nodule of the left
temporal region of the patient. (B) Ultrasonography
demonstrates wall thickening of the temporal artery
(arrow) with (C) normal colour Doppler pattern (arrow);
arrowheads indicate the outer table of the skull. (D)
Hyperintense tissue around the vessel is demonstrated by
MRI Fast SpinEcho T2-weighted fat-suppressed coronal
sequences (arrow). (E) CD34 immunohistochemical
staining, 20 . Lymphoid follicles (F).
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